Clinical Trial Update: A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of atezolizumab with allogeneic natural killer cell therapy in adults with relapsed or refractory acute myeloid leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Allogeneic natural killer cell therapy (Allogeneic NK cell therapy)
• Atezolizumab (atezolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse | Phase 1 | Status: RECRUITING